Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC).

Publication ,  Conference
Halabi, S; Ou, S; Vogelzang, NJ; Small, EJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 20, 2006

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

June 20, 2006

Volume

24

Issue

18

Start / End Page

230S / 230S

Location

Atlanta, GA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Halabi, S., Ou, S., Vogelzang, N. J., & Small, E. J. (2006). An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 24, pp. 230S-230S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY.
Halabi, S., S. Ou, N. J. Vogelzang, and E. J. Small. “An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC).” In JOURNAL OF CLINICAL ONCOLOGY, 24:230S-230S. AMER SOC CLINICAL ONCOLOGY, 2006.
Halabi S, Ou S, Vogelzang NJ, Small EJ. An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 230S-230S.
Halabi, S., et al. “An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC).JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. 18, AMER SOC CLINICAL ONCOLOGY, 2006, pp. 230S-230S.
Halabi S, Ou S, Vogelzang NJ, Small EJ. An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 230S-230S.

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

June 20, 2006

Volume

24

Issue

18

Start / End Page

230S / 230S

Location

Atlanta, GA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences